<DOC>
	<DOCNO>NCT00316420</DOCNO>
	<brief_summary>The purpose study test effectiveness safety drug combination gemcitabine capecitabine ( Xeloda ) patient advanced pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine Capecitabine Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Metastatic unresectable pancreatic cancer No prior chemotherapy except radiationsensitizing dos 5FU No radiotherapy less 4 week prior start study Prior unanticipated severe reaction fluoropyrimidine therapy know hypersensitivity 5FU Moderate severe renal impairment Uncontrolled diabetes Inability swallow tablet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>